Half of one group had tumor responses, including unconfirmed cases, in a cancer trial.

Perspective Therapeutics reported interim results for VMT-α-NET, showing 33% and 50% objective response rates in two dose cohorts and 72% progression-free survival at 18 months across all cohorts. The company plans to initiate Phase 3 trials in 2027, pending regulatory alignment.

Perspective Therapeutics (CATX) reported interim Phase 1/2a trial results for [212Pb]VMT-α-NET in neuroendocrine tumor patients. Cohort 2 showed 33% response rate (n=46) and Cohort 3 showed 50% (n=20). Disease control rates were 89% and 95% respectively. No severe adverse events were reported. The company plans to initiate Phase 3 trials in 2027.

Perspective Therapeutics, Inc. (CATX) filed an SEC Form 8-K — Other Events. Perspective’s [212Pb]Bamzireotide Navoxetan (VMT-α-NET) Demonstrates Encouraging Safety, Durable Disease Control, and Robust Tumor Response Across Multiple Dose Cohorts in Phase 1/2a Trial in Advanced SSTR2-Expressing NETs • Results presented at ESMO show a promising therapeutic

Perspective Therapeutics (CATX) reported interim Phase 1/2a data for [212Pb]VMT-α-NET in SSTR2+ NETs, showing ORRs of 33% and 50% at different doses, 72% PFS at 18 months, and no serious adverse events. The company aims to start Phase 3 trials in 2027.

Perspective Therapeutics (CATX) announced FDA Fast Track Designation for PSV359, a treatment for FAP-positive SFTs. The drug is in a Phase 1/2a study, showing early signs of tumor uptake. CATX stock rose 4.24% to $2.46 on Wednesday.

Perspective Therapeutics (CATX) received FDA Fast Track designation for PSV359, an investigational FAP-targeted alpha therapy, to treat adult patients with locally advanced or metastatic FAP-positive solitary fibrous tumors. The drug is currently in a Phase 1/2a study, with early human imaging showing promising results. Fast Track designation may expedite development and review processes.